Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher Friday after the company announced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy treatment program.Mangoceuticals stock is among today’s top performers. What’s behind MGRX gains?Early Traction Validates $99 Subscription ModelThe company said month-over-month sales of its injectable TRT program increased 336% since launching in mid-December. MangoRx also reported a 54% reduction in customer acquisi ...